XNAS · Healthcare · Biotechnology
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q3 2026 | — | -0.28 | — | $0 | — | +1.23% | -5.34% | — |
| 2026-02-17 | Q2 2026 | — | -0.30 | — | $0 | — | -4.50% | -4.50% | -46.79% |
| 2025-11-17 | Q1 2026 |
| — |
| -0.39 |
| — |
| $0 |
| — |
| — |
| — |
| — |
Showing last 3 quarters.